CellProtect Nordic Pharmaceuticals AB Information

CellProtect Nordic Pharmaceuticals AB (CPNP) develops innovative new cell therapies to treat severe diseases. The lead program is CellProtect, ex vivo activated and expanded Natural killer (NK) cells for treatment of multiple myeloma. CPNP has established a protocol for expansion and restoration of cytotoxic activity of the NK cells, thereby offering patients a new and potentially curative treatment. CellProtect is currently in Phase I clinical trials as adjunct treatment to autologous stem cell transplantation in patients with multiple myeloma. The Phase I study is conducted at the Karolinska University Hospital, Huddinge, Sweden.